Logo

Sirna Wraps Up $18.7M Private Placement

May 05, 2004

NEW YORK, May 5 (GenomeWeb News) -- Sirna Therapeutics has closed an $18.7 million private placement of its common stock to undisclosed institutional investors, the company said today.

 

The Boulder, Colo.-based RNAi developer sold 5.8 million of its common shares in the transaction.

Breaking News
The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.